As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index, which ...

Given a list of 40 drugmakers, the respondents rated ViiV most highly in terms of corporate reputation, followed by ...

Eisai has put direct-to-consumer (DTC) advertising at the heart of its ongoing efforts to expand demand for Leqembi. | Eisai ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced the risk of severe exacerbations by 47% compared to albuterol, the ...

On a mission to expand its recently approved Tryngolza beyond the rare genetic disorder familial chylomicronemia syndrome ...

With $27 billion earmarked to expand its U.S. production footprint starting this year, Eli Lilly is busy scouting out ...